Showing results (71-80 of 290) with videos related to
Sort By:
Pageof 29
Journal of Hematology & Oncology|January 16, 2014
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion proteinVivek Subbiah, Shannon N Westin, Kai Wang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to AlectinibSai-Hong Ignatius Ou, Samuel J Klempner, Joel R Greenbowe, et al.Nature|March 25, 2011
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFRTrever G Bivona, Haley Hieronymus, Joel Parker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2011
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayMaria E Arcila, Geoffrey R Oxnard, Khedoudja Nafa, et al.Cancer|May 19, 2012
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomasPaul K Paik, Melissa L Johnson, Sandra P D'Angelo, et al.Cancer|April 7, 2005
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trialLee M Krug, John P Crapanzano, Christopher G Azzoli, et al.Cold Spring Harbor Molecular Case Studies|May 28, 2017
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an <i>STK11</i> variantChristine A Parachoniak, Andrew Rankin, Bernadette Gaffney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusGregory J Riely, Mark G Kris, Binsheng Zhao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomasSandra P D'Angelo, M Catherine Pietanza, Melissa L Johnson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2004
Practical management of patients with non-small-cell lung cancer treated with gefitinibNeelam T Shah, Mark G Kris, William Pao, et al.Pageof 29